VivoSeq
Other

AGA

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

AGA is an early-stage landscape with 0 programs across 1 company. The most active players are Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed6 · 86%
Unknown status1 · 14%

Clinical Trials

Trial Activity

7 trials

A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)
Completed·—·Phase 2·NCT00961662·161 enrolled
48 Hours Esophagal pH-monitoring With and Without Gaviscon
Completed·UUniversitair Ziekenhuis Brussel·N/A·NCT02783378·50 enrolled
Validation of a Non Invasive Blood Marker of SIDS and Vagal Disorders
Completed·UUniversity Hospital, Strasbourg, France·N/A·NCT01358461·240 enrolled
Gammagard Liquid and rHuPH20 in PID
Completed·BBaxalta now part of Shire·Phase 3·NCT00814320·89 enrolled
A Study of Semagacestat for Alzheimer's Patients
Completed·Eli Lilly logoEli Lilly·Phase 3·NCT01035138·180 enrolled
Neuropeptide Y and Sympathovagal Balance
Completed·—·Phase 1·NCT03933787·7 enrolled
Propagation Waves in Tactile Material Perception
Unknown status·RReinier Haga Orthopedisch Centrum·N/A·NCT05253508·15 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)